Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Damora Therapeutics, Inc stake
total: 670
Viking Global Investors DMRA trades
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Ole Andreas Halvorsen holds 2,311,082 Damora Therapeutics, Inc (DMRA) shares with a market value of roughly $60.11M accounting for 0.17% of the overall portfolio. To date, the estimated cost basis is nearly $25.9 for "buy" trades. Viking Global Investors first purchased DMRA in 2026 Q1, initially acquiring about 2.31M shares.
When did Ole Andreas Halvorsen buy Damora Therapeutics, Inc (DMRA)?
Ole Andreas Halvorsen first invested in Damora Therapeutics, Inc (DMRA) in 2026 Q1 at the reported quarter-end price of $25.90 per share.
What's the cost basis of Viking Global Investors's DMRA stake?
The estimated cost basis for Damora Therapeutics, Inc (DMRA) stake is around $25.90 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $25.90
Ole Andreas Halvorsen's historical trades in Damora Therapeutics, Inc
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.17%
|
2,311,082
|
$25.90
|
$59,857,024
|
new
|
+0.17%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.